Literature DB >> 25004844

Safety and infectious prophylaxis of intravenous immunoglobulin in elderly patients with membranous nephropathy.

I Molinaro1, B Barbano2, E Rosato1, R Cianci2, F Di Mario3, S Quarta1, L Sardo3, F Salsano1, A Amoroso3, A Gigante3.   

Abstract

A variety of infections has been recognized as an important cause of morbidity and mortality in patients with nephrotic syndrome, and membranous nephropathy is a common cause of this in the elderly. The reasons for infection risk are due to oedema complications, urinary loss of factor B and D of the alternative complement pathway, cellular immunity, granulocyte chemotaxis, hypogammaglobulinemia with serum IgG levels below 600 mg/dL, and secondary effects of immunosuppressive therapy. Many different prophylactic interventions have been used for reducing the risks of infection in these patients but recommendations for routine use are still lacking. We report two membranous nephropathy cases in the elderly in which Intravenous immunoglobulin were useful in long-term infectious prophylaxis, showing safety in renal function. During immunosuppressant therapy in membranous nephropathy, intravenous immunoglobulin without sucrose are a safe therapeutic option as prophylaxis in those patients with nephrotic syndrome and IgG levels below 600 mg/dL. The long-term goal of infection prevention in these patients is to reduce mortality, prolong survival and improve quality of life.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25004844     DOI: 10.1177/039463201402700220

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  3 in total

1.  Immunosuppression in idiopathic membranous nephropathy: A double-edge sword.

Authors:  Vincenzo L'Imperio; Elena Ajello; Maurizio Garozzo; Antonella Tosoni; Franco Ferrario; Fabio Pagni
Journal:  Int J Immunopathol Pharmacol       Date:  2016-07-06       Impact factor: 3.219

Review 2.  Immunoglobulin replacement therapy in secondary hypogammaglobulinemia.

Authors:  Nicolò Compagno; Giacomo Malipiero; Francesco Cinetto; Carlo Agostini
Journal:  Front Immunol       Date:  2014-12-08       Impact factor: 7.561

3.  Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy.

Authors:  Christine Barrett; Lisa C Willcocks; Rachel B Jones; Ruth M Tarzi; Robert B Henderson; Gengqian Cai; Sophie I Gisbert; Alexandra S Belson; Caroline O Savage
Journal:  Nephrol Dial Transplant       Date:  2020-04-01       Impact factor: 5.992

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.